Daybue
Daybue ingredients
| Active ingredient | Strength |
|---|---|
| Trofinetide | 200 mg/mL |
What Daybue is used for
The FDA lists the approved uses on the official label (below). In the EU, trofinetide is approved as Daybu for:
Daybu is indicated for the treatment of neurobehavioural symptoms of Rett syndrome in adults and paediatric patients aged 5 years and older.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Daybue
- Generic name
- Trofinetide
- Made by
- Acadia Pharmaceuticals Inc.
- Forms
- Solution
- Given
- Oral
- FDA approval
- New drug application (NDA) NDA217026
- On the US market since
- 2023
Official information
- Daybue prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Trofinetide)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Daybue?
Daybue (Trofinetide) is a specialist medicine made by Acadia Pharmaceuticals Inc., approved by the US FDA.
What are the ingredients of Daybue?
Daybue contains Trofinetide (200 mg/mL).
Is Daybue approved in Europe?
The same active substance is approved in the EU as Daybu.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA